Please assess the completion status of the following clinical trial:

Trial Title: Mucosal Healing Study in Crohn's Disease (CD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients suffering from active Crohn's disease \[Crohn's Disease Activity Index(CDAI) ≥ 220 and ≤ 450\] and at least 2 segments with endoscopic ulcerative lesions with Baseline Crohn's Disease Endoscopic Index of Severity (CDEIS) ≥ 8~* Patients who need to be treated by anti-tumor necrosis factor (anti-TNF) therapy~Exclusion Criteria:~* Obstructive intestinal strictures, bowel resection, proctocolectomy or total colectomy, current total parenteral nutrition, short bowel syndrome~* History of tuberculosis or positive tests for tuberculosis at screening~* All the concomitant diseases or pathological conditions that could interfere with Crohn's disease assessment or to be harmful for the well being of the patient~* Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CDP870 400 mg (Type: EXPERIMENTAL): Certolizumab pegol (CDP870) 400 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).